Upifitamab rilsodotin not checked
Mersana Therapeutics · XMT-1536 Antibody Drug Conjugate · XMT-1536
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study. For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential…”In the company’s words, NCT03319628 on ClinicalTrials.gov
- Main trialPhase 1/2
- “First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer were enrolled in the UPLIFT segment of this study. In addition to safety assessments, the pharmacokinetics of the…”In the company’s words, NCT03319628 on ClinicalTrials.gov
- Other names
- Upifitimab rilsodotin · XMT-1536 Antibody Drug Conjugate · XMT-1536 · UpRi
Other drugs for Platinum Resistant Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab soravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 May 2023 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | |
| Phase 3Terminated | 29 Sep 2023 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | |
| Phase 1Completed | 9 Jul 2021 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | |
| Phase 1Completed | 31 May 2022 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | |
| Phase 1Terminated | 3 Oct 2023 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026